Dipartimento di Scienze Farmaceutiche e Biomediche, Università di Salerno, Via Ponte don Melillo, 84084 Fisciano (SA), Italy.
Bioorg Med Chem. 2011 Nov 1;19(21):6419-29. doi: 10.1016/j.bmc.2011.08.062. Epub 2011 Sep 1.
A series of trisubstituted naphthalimides have been synthesized and evaluated as telomeric G-quadruplex ligands by biophysical methods. Affinity for telomeric G-quadruplex AGGG(TTAGGG)(3) binding was first screened by fluorescence titrations. Subsequently, the interaction of the telomeric G-quadruplex with compounds showing the best affinity has been studied by isothermal titration calorimetry and UV-melting experiments. The two best compounds of the series tightly bind the telomeric quadruplex with a 2:1 drug/DNA stoichiometry. These derivatives have been further evaluated for their ability to inhibit telomerase by a TRAP assay and their pharmacological properties by treating melanoma (M14) and human lung cancer (A549) cell lines with increasing drug concentrations. A dose-dependent inhibition of cell proliferation was observed for all cellular lines during short-term treatment.
通过生物物理方法,我们合成了一系列三取代萘酰亚胺,并将其评估为端粒 G-四链体配体。通过荧光滴定首先筛选了与端粒 G-四链体 AGGG(TTAGGG)(3) 结合的亲和力。随后,通过等温滴定量热法和 UV 熔融实验研究了与表现出最佳亲和力的化合物的端粒 G-四链体相互作用。该系列中的两个最佳化合物与端粒四联体紧密结合,药物/DNA 比例为 2:1。进一步通过端粒酶重复扩增 (TRAP) 测定和用增加药物浓度处理黑素瘤 (M14) 和人肺癌 (A549) 细胞系来评估这些衍生物抑制端粒酶的能力及其药理学特性。在短期治疗期间,所有细胞系均观察到剂量依赖性的细胞增殖抑制。